Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire
– ARCALYST^® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –
–..
– ARCALYST^® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –
–..
*LITTLETON, CO / ACCESSWIRE / April 8, 2024 /* *Ur-Energy Inc. *(NYSE American:URG)(TSX:URE) (the "Company" or "Ur-Energy") is..
Bringing youth to the forefront in advancing climate solutions
HAMILTON, Ontario, March 05, 2024 (GLOBE NEWSWIRE) --..